PT-141 (Bremelanotide)

PT-141 (bremelanotide) is a synthetic peptide that research indicates acts as a melanocortin receptor agonist, primarily targeting MC4R receptors in the hypothalamus. Originally developed from the tanning peptide Melanotan II, studies suggest PT-141 influences sexual arousal through central nervous system pathways rather than vascular mechanisms. The FDA approved it in 2019 as Vyleesi for treating hypoactive sexual desire disorder in premenopausal women, administered via subcutaneous injection.

Clinical trials indicate that PT-141 may increase sexual desire and arousal through activation of melanocortin pathways in the brain. Research suggests the compound works by stimulating dopaminergic and noradrenergic signaling in areas associated with sexual motivation. Beyond its approved indication, some studies explore its potential metabolic effects, as melanocortin receptors play roles in energy homeostasis and appetite regulation.

Research indicates common side effects include nausea, flushing, and injection site reactions, with some studies noting transient increases in blood pressure and heart rate. The compound requires subcutaneous injection and is typically used on an as-needed basis rather than daily dosing. While approved for a specific indication in women, off-label research and use in other populations continues, though long-term safety data remains limited.